Skip to main content
Top
Published in: Langenbeck's Archives of Surgery 6/2017

01-09-2017 | REVIEW ARTICLE

Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia

Authors: Ajay V. Maker, Raashid Sheikh, Vinita Bhagia, Diabetes Control and Complications Trial (DCCT) Research Group

Published in: Langenbeck's Archives of Surgery | Issue 6/2017

Login to get access

Abstract

Purpose

Indications for total pancreatectomy (TP) have increased, including for diffuse main duct intrapapillary mucinous neoplasms of the pancreas and malignancy; therefore, the need persists for surgeons to develop appropriate endocrine post-operative management strategies. The brittle diabetes after TP differs from type 1/2 diabetes in that patients have absolute deficiency of insulin and functional glucagon. This makes glucose management challenging, complicates recovery, and predisposes to hospital readmissions. This article aims to define the disease, describe the cause for its occurrence, review the anatomy of the endocrine pancreas, and explain how this condition differs from diabetes mellitus in the setting of post-operative management. The morbidity and mortality of post-TP endocrine insufficiency and practical treatment strategies are systematically reviewed from the literature. Finally, an evidence-based treatment algorithm is created for the practicing pancreatic surgeon and their care team of endocrinologists to aid in managing these complex patients.

Methods

A PubMed, Science Citation Index/Social sciences Citation Index, and Cochrane Evidence-Based Medicine database search was undertaken along with extensive backward search of the references of published articles to identify studies evaluating endocrine morbidity and treatment after TP and to establish an evidence-based treatment strategy.

Results

Indications for TP and the etiology of pancreatogenic diabetes are reviewed. After TP, ~80% patients develop hypoglycemic episodes and 40% experience severe hypoglycemia, resulting in 0–8% mortality and 25–45% morbidity. Referral to a nutritionist and endocrinologist for patient education before surgery followed by surgical reevaluation to determine if the patient has the appropriate understanding, support, and resources preoperatively has significantly reduced morbidity and mortality. The use of modern recombinant long-acting insulin analogues, continuous subcutaneous insulin infusion, and glucagon rescue therapy has greatly improved management in the modern era and constitute the current standard of care. A simple immediate post-operative algorithm was constructed.

Conclusion

Successful perioperative surgical management of total pancreatectomy and resulting pancreatogenic diabetes is critical to achieve acceptable post-operative outcomes, and we review the pertinent literature and provide a simple, evidence-based algorithm for immediate post-resection glycemic control.
Literature
2.
go back to reference Blanchet MC, Andreelli F, Scoazec JY, Le Borgne J, Ozoux P, De Calan L et al (2002) Total pancreatectomy for mucinous pancreatic tumor. Ann Chir 127(6):439–448PubMedCrossRef Blanchet MC, Andreelli F, Scoazec JY, Le Borgne J, Ozoux P, De Calan L et al (2002) Total pancreatectomy for mucinous pancreatic tumor. Ann Chir 127(6):439–448PubMedCrossRef
3.
go back to reference Sauvanet A (2008) Intraductal papillary mucinous neoplasms of the pancreas: indication, extent, and results of surgery. Surg Oncol Clin N Am 17(3):587–606 ixPubMedCrossRef Sauvanet A (2008) Intraductal papillary mucinous neoplasms of the pancreas: indication, extent, and results of surgery. Surg Oncol Clin N Am 17(3):587–606 ixPubMedCrossRef
4.
go back to reference Yamaguchi K, Konomi H, Kobayashi K, Ogura Y, Sonoda Y, Kawamoto M et al (2005) Total pancreatectomy for intraductal papillary-mucinous tumor of the pancreas: reappraisal of total pancreatectomy. Hepato-Gastroenterology 52(65):1585–1590PubMed Yamaguchi K, Konomi H, Kobayashi K, Ogura Y, Sonoda Y, Kawamoto M et al (2005) Total pancreatectomy for intraductal papillary-mucinous tumor of the pancreas: reappraisal of total pancreatectomy. Hepato-Gastroenterology 52(65):1585–1590PubMed
5.
6.
go back to reference Willens D, Cripps R, Wolff K, Rothman R (2011) Interdisciplinary team care for diabetic patients by primary care physicians, advanced practice nurses, and clinical pharmacists. Clin Diabetes 29(2):60–68CrossRef Willens D, Cripps R, Wolff K, Rothman R (2011) Interdisciplinary team care for diabetic patients by primary care physicians, advanced practice nurses, and clinical pharmacists. Clin Diabetes 29(2):60–68CrossRef
9.
go back to reference Pickup JC, Home PD, Bilous RW, Keen H, Alberti KG (1981) Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption. Br Med J (Clin Res Ed) 282(6261):347–350CrossRef Pickup JC, Home PD, Bilous RW, Keen H, Alberti KG (1981) Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption. Br Med J (Clin Res Ed) 282(6261):347–350CrossRef
10.
go back to reference Muller WA, Brennan MF, Tan MH, Aoki TT (1974) Studies of glucagon secretion in pancreatectomized patients. Diabetes 23(6):512–516PubMedCrossRef Muller WA, Brennan MF, Tan MH, Aoki TT (1974) Studies of glucagon secretion in pancreatectomized patients. Diabetes 23(6):512–516PubMedCrossRef
11.
go back to reference Vigili de Kreutzenberg S, Maifreni L, Lisato G, Riccio A, Trevisan R, Tiengo A et al (1990) Glucose turnover and recycling in diabetes secondary to total pancreatectomy: effect of glucagon infusion. J Clin Endocrinol Metab 70(4):1023–1029PubMedCrossRef Vigili de Kreutzenberg S, Maifreni L, Lisato G, Riccio A, Trevisan R, Tiengo A et al (1990) Glucose turnover and recycling in diabetes secondary to total pancreatectomy: effect of glucagon infusion. J Clin Endocrinol Metab 70(4):1023–1029PubMedCrossRef
12.
go back to reference Nosadini R, del Prato S, Tiengo A, Duner E, Toffolo G, Cobelli C et al (1982) Insulin sensitivity, binding, and kinetics in pancreatogenic and type I diabetes. Diabetes 31(4 Pt 1):346–355PubMedCrossRef Nosadini R, del Prato S, Tiengo A, Duner E, Toffolo G, Cobelli C et al (1982) Insulin sensitivity, binding, and kinetics in pancreatogenic and type I diabetes. Diabetes 31(4 Pt 1):346–355PubMedCrossRef
13.
go back to reference Boyle PJ (1997) Alteration in brain glucose metabolism induced by hypoglycaemia in man. Diabetologia 40(Suppl 2):S69–S74PubMedCrossRef Boyle PJ (1997) Alteration in brain glucose metabolism induced by hypoglycaemia in man. Diabetologia 40(Suppl 2):S69–S74PubMedCrossRef
14.
go back to reference Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV (1988) Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 37(7):901–907PubMedCrossRef Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV (1988) Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 37(7):901–907PubMedCrossRef
15.
go back to reference Horie H, Matsuyama T, Namba M, Itoh H, Nonaka K, Tarui S et al (1984) Responses of catecholamines and other counterregulatory hormones to insulin-induced hypoglycemia in totally pancreatectomized patients. J Clin Endocrinol Metab 59(6):1193–1196PubMedCrossRef Horie H, Matsuyama T, Namba M, Itoh H, Nonaka K, Tarui S et al (1984) Responses of catecholamines and other counterregulatory hormones to insulin-induced hypoglycemia in totally pancreatectomized patients. J Clin Endocrinol Metab 59(6):1193–1196PubMedCrossRef
16.
go back to reference Bonner-Weir S (1991) Anatomy of islet of Langerhans. In: Samols E (ed) The endocrine pancreas. Raven Press Bonner-Weir S (1991) Anatomy of islet of Langerhans. In: Samols E (ed) The endocrine pancreas. Raven Press
17.
go back to reference Klover PJ, Mooney RA (2004) Hepatocytes: critical for glucose homeostasis. Int J Biochem Cell Biol 36(5):753–758PubMedCrossRef Klover PJ, Mooney RA (2004) Hepatocytes: critical for glucose homeostasis. Int J Biochem Cell Biol 36(5):753–758PubMedCrossRef
19.
go back to reference Kahn BB (1996) Lilly lecture 1995. Glucose transport: pivotal step in insulin action. Diabetes 45(11):1644–1654PubMedCrossRef Kahn BB (1996) Lilly lecture 1995. Glucose transport: pivotal step in insulin action. Diabetes 45(11):1644–1654PubMedCrossRef
22.
go back to reference Beglinger C, Drewe J (1999) Somatostatin and octreotide: physiological background and pharmacological application. Digestion 60(Suppl 2):2–8 doi:51474PubMedCrossRef Beglinger C, Drewe J (1999) Somatostatin and octreotide: physiological background and pharmacological application. Digestion 60(Suppl 2):2–8 doi:51474PubMedCrossRef
23.
go back to reference McCann SM, Krulich L, Negro-Vilar A, Ojeda SR, Vijayan E (1980) Regulation and function of panhibin (somatostatin). Adv Biochem Psychopharmacol 22:131–143PubMed McCann SM, Krulich L, Negro-Vilar A, Ojeda SR, Vijayan E (1980) Regulation and function of panhibin (somatostatin). Adv Biochem Psychopharmacol 22:131–143PubMed
25.
go back to reference Muller MW, Friess H, Kleeff J, Dahmen R, Wagner M, Hinz U et al (2007) Is there still a role for total pancreatectomy? Ann Surg 246(6):966–974 discussion 74-5 PubMedCrossRef Muller MW, Friess H, Kleeff J, Dahmen R, Wagner M, Hinz U et al (2007) Is there still a role for total pancreatectomy? Ann Surg 246(6):966–974 discussion 74-5 PubMedCrossRef
27.
go back to reference Hruban RH, Goggins M, Parsons J, Kern SE (2000) Progression model for pancreatic cancer. Clin Cancer Res 6(8):2969–2972PubMed Hruban RH, Goggins M, Parsons J, Kern SE (2000) Progression model for pancreatic cancer. Clin Cancer Res 6(8):2969–2972PubMed
28.
go back to reference Kekis PB, Friess H, Kleeff J, Buchler MW (2001) Timing and extent of surgical intervention in patients from hereditary pancreatic cancer kindreds. Pancreatology 1(5):525–530PubMedCrossRef Kekis PB, Friess H, Kleeff J, Buchler MW (2001) Timing and extent of surgical intervention in patients from hereditary pancreatic cancer kindreds. Pancreatology 1(5):525–530PubMedCrossRef
29.
go back to reference Sarr MG, Kendrick ML, Nagorney DM, Thompson GB, Farley DR, Farnell MB (2001) Cystic neoplasms of the pancreas: benign to malignant epithelial neoplasms. Surg Clin North Am 81(3):497–509PubMedCrossRef Sarr MG, Kendrick ML, Nagorney DM, Thompson GB, Farley DR, Farnell MB (2001) Cystic neoplasms of the pancreas: benign to malignant epithelial neoplasms. Surg Clin North Am 81(3):497–509PubMedCrossRef
34.
go back to reference Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64(7):2634–2638PubMedCrossRef Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64(7):2634–2638PubMedCrossRef
36.
go back to reference Brentnall TA (2005) Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options in Oncol 6(5):437–445CrossRef Brentnall TA (2005) Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options in Oncol 6(5):437–445CrossRef
38.
go back to reference Hartel M, Wente MN, Di Sebastiano P, Friess H, Buchler MW (2004) The role of extended resection in pancreatic adenocarcinoma: is there good evidence-based justification? Pancreatology 4(6):561–566PubMedCrossRef Hartel M, Wente MN, Di Sebastiano P, Friess H, Buchler MW (2004) The role of extended resection in pancreatic adenocarcinoma: is there good evidence-based justification? Pancreatology 4(6):561–566PubMedCrossRef
39.
go back to reference Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S (2006) Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 10(4):511–518PubMedCrossRef Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S (2006) Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 10(4):511–518PubMedCrossRef
40.
41.
go back to reference Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91(5):586–594. doi:10.1002/bjs.4484 PubMedCrossRef Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91(5):586–594. doi:10.​1002/​bjs.​4484 PubMedCrossRef
42.
go back to reference Schmidt CM, Glant J, Winter JM, Kennard J, Dixon J, Zhao Q et al (2007) Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma. Surgery 142(4):572–578 discussion 8-80 PubMedCrossRef Schmidt CM, Glant J, Winter JM, Kennard J, Dixon J, Zhao Q et al (2007) Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma. Surgery 142(4):572–578 discussion 8-80 PubMedCrossRef
46.
go back to reference Welsch T, Frommhold K, Hinz U, Weigand MA, Kleeff J, Friess H et al (2008) Persisting elevation of C-reactive protein after pancreatic resections can indicate developing inflammatory complications. Surgery 143(1):20–28PubMedCrossRef Welsch T, Frommhold K, Hinz U, Weigand MA, Kleeff J, Friess H et al (2008) Persisting elevation of C-reactive protein after pancreatic resections can indicate developing inflammatory complications. Surgery 143(1):20–28PubMedCrossRef
47.
go back to reference Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J et al (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10(9):1199–1210 discussion 210-1 PubMedCrossRef Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J et al (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10(9):1199–1210 discussion 210-1 PubMedCrossRef
49.
go back to reference Bartoli FG, Arnone GB, Ravera G, Bachi V (1991) Pancreatic fistula and relative mortality in malignant disease after pancreaticoduodenectomy. Review and statistical meta-analysis regarding 15 years of literature. Anticancer Res 11(5):1831–1848PubMed Bartoli FG, Arnone GB, Ravera G, Bachi V (1991) Pancreatic fistula and relative mortality in malignant disease after pancreaticoduodenectomy. Review and statistical meta-analysis regarding 15 years of literature. Anticancer Res 11(5):1831–1848PubMed
50.
go back to reference Buchler MW, Kleeff J, Friess H (2007) Surgical treatment of pancreatic cancer. J Am Coll Surg 205(4 Suppl):S81–S86PubMedCrossRef Buchler MW, Kleeff J, Friess H (2007) Surgical treatment of pancreatic cancer. J Am Coll Surg 205(4 Suppl):S81–S86PubMedCrossRef
51.
go back to reference Lin JW, Cameron JL, Yeo CJ, Riall TS, Lillemoe KD (2004) Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg 8(8):951–959PubMedCrossRef Lin JW, Cameron JL, Yeo CJ, Riall TS, Lillemoe KD (2004) Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg 8(8):951–959PubMedCrossRef
52.
go back to reference Muscari F, Suc B, Kirzin S, Hay JM, Fourtanier G, Fingerhut A et al (2006) Risk factors for mortality and intra-abdominal complications after pancreatoduodenectomy: multivariate analysis in 300 patients. Surgery 139(5):591–598PubMedCrossRef Muscari F, Suc B, Kirzin S, Hay JM, Fourtanier G, Fingerhut A et al (2006) Risk factors for mortality and intra-abdominal complications after pancreatoduodenectomy: multivariate analysis in 300 patients. Surgery 139(5):591–598PubMedCrossRef
53.
go back to reference van Berge Henegouwen MI, De Wit LT, Van Gulik TM, Obertop H, Gouma DJ (1997) Incidence, risk factors, and treatment of pancreatic leakage after pancreaticoduodenectomy: drainage versus resection of the pancreatic remnant. J Am Coll Surg 185(1):18–24PubMedCrossRef van Berge Henegouwen MI, De Wit LT, Van Gulik TM, Obertop H, Gouma DJ (1997) Incidence, risk factors, and treatment of pancreatic leakage after pancreaticoduodenectomy: drainage versus resection of the pancreatic remnant. J Am Coll Surg 185(1):18–24PubMedCrossRef
54.
go back to reference Singh VV, Toskes PP (2003) Medical therapy for chronic pancreatitis pain. Curr Gastroenterol Rep 5(2):110–116PubMedCrossRef Singh VV, Toskes PP (2003) Medical therapy for chronic pancreatitis pain. Curr Gastroenterol Rep 5(2):110–116PubMedCrossRef
55.
go back to reference Madsen P, Winkler K (1982) The intraductal pancreatic pressure in chronic obstructive pancreatitis. Scand J Gastroenterol 17(4):553–554PubMedCrossRef Madsen P, Winkler K (1982) The intraductal pancreatic pressure in chronic obstructive pancreatitis. Scand J Gastroenterol 17(4):553–554PubMedCrossRef
56.
57.
go back to reference Karanjia ND, Widdison AL, Leung F, Alvarez C, Lutrin FJ, Reber HA (1994) Compartment syndrome in experimental chronic obstructive pancreatitis: effect of decompressing the main pancreatic duct. Br J Surg 81(2):259–264PubMedCrossRef Karanjia ND, Widdison AL, Leung F, Alvarez C, Lutrin FJ, Reber HA (1994) Compartment syndrome in experimental chronic obstructive pancreatitis: effect of decompressing the main pancreatic duct. Br J Surg 81(2):259–264PubMedCrossRef
60.
go back to reference Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS et al (2007) Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg 11(11):1460–1467; discussion 7-9. doi:10.1007/s11605-007-0263-3 PubMedCrossRef Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS et al (2007) Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg 11(11):1460–1467; discussion 7-9. doi:10.​1007/​s11605-007-0263-3 PubMedCrossRef
61.
go back to reference Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF et al (2007) Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 25(35):5609–5615. doi:10.1200/jco.2007.12.9809 PubMedCrossRef Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF et al (2007) Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 25(35):5609–5615. doi:10.​1200/​jco.​2007.​12.​9809 PubMedCrossRef
62.
65.
go back to reference Thompson GB, Service FJ, van Heerden JA, Carney JA, Charboneau JW, O’Brien PC et al (1993) Reoperative insulinomas, 1927 to 1992: an institutional experience. Surgery 114(6):1196–1204 discussion 205-6 PubMed Thompson GB, Service FJ, van Heerden JA, Carney JA, Charboneau JW, O’Brien PC et al (1993) Reoperative insulinomas, 1927 to 1992: an institutional experience. Surgery 114(6):1196–1204 discussion 205-6 PubMed
66.
go back to reference Gould VE, Chejfec G, Shah K, Paloyan E, Lawrence AM (1984) Adult nesidiodysplasia. Semin Diagn Pathol 1(1):43–53PubMed Gould VE, Chejfec G, Shah K, Paloyan E, Lawrence AM (1984) Adult nesidiodysplasia. Semin Diagn Pathol 1(1):43–53PubMed
67.
go back to reference Walmsley D, Matheson NA, Ewen S, Himsworth RL, Bevan JS (1995) Nesidioblastosis in an elderly patient. Diabet Med 12(6):542–545PubMedCrossRef Walmsley D, Matheson NA, Ewen S, Himsworth RL, Bevan JS (1995) Nesidioblastosis in an elderly patient. Diabet Med 12(6):542–545PubMedCrossRef
68.
go back to reference Bjerke HS, Kelly RE Jr, Geffner ME, Fonkalsrud EW (1990) Surgical management of islet cell dysmaturation syndrome in young children. Surg Gynecol Obstet 171(4):321–325PubMed Bjerke HS, Kelly RE Jr, Geffner ME, Fonkalsrud EW (1990) Surgical management of islet cell dysmaturation syndrome in young children. Surg Gynecol Obstet 171(4):321–325PubMed
69.
go back to reference Kramer JL, Bell MJ, DeSchryver K, Bower RJ, Ternberg JL, White NH (1982) Clinical and histologic indications for extensive pancreatic resection in nesidioblastosis. Am J Surg 143(1):116–119PubMedCrossRef Kramer JL, Bell MJ, DeSchryver K, Bower RJ, Ternberg JL, White NH (1982) Clinical and histologic indications for extensive pancreatic resection in nesidioblastosis. Am J Surg 143(1):116–119PubMedCrossRef
70.
go back to reference Langer JC, Filler RM, Wesson DE, Sherwood G, Cutz E (1984) Surgical management of persistent neonatal hypoglycemia due to islet cell dysplasia. J Pediatr Surg 19(6):786–792PubMedCrossRef Langer JC, Filler RM, Wesson DE, Sherwood G, Cutz E (1984) Surgical management of persistent neonatal hypoglycemia due to islet cell dysplasia. J Pediatr Surg 19(6):786–792PubMedCrossRef
71.
go back to reference Moazam F, Rodgers BM, Talbert JL, Rosenbloom AL (1982) Near-total pancreatectomy in persistent infantile hypoglycemia. Arch Surg 117(9):1151–1154PubMedCrossRef Moazam F, Rodgers BM, Talbert JL, Rosenbloom AL (1982) Near-total pancreatectomy in persistent infantile hypoglycemia. Arch Surg 117(9):1151–1154PubMedCrossRef
72.
go back to reference Del Chiaro M, Zerbi A, Capurso G, Zamboni G, Maisonneuve P, Presciuttini S et al (2010) Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: a position paper from the Italian Registry. Dig Liver Dis 42(9):597–605PubMedCrossRef Del Chiaro M, Zerbi A, Capurso G, Zamboni G, Maisonneuve P, Presciuttini S et al (2010) Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: a position paper from the Italian Registry. Dig Liver Dis 42(9):597–605PubMedCrossRef
74.
75.
go back to reference MacLeod KM, Hepburn DA, Frier BM (1993) Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 10(3):238–245PubMedCrossRef MacLeod KM, Hepburn DA, Frier BM (1993) Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 10(3):238–245PubMedCrossRef
76.
go back to reference Warren KW, Poulantzas JK, Kune GA (1966) Life after total pancreatectomy for chronic pancreatitis: clinical study of eight cases. Ann Surg 164(5):830–834PubMedPubMedCentralCrossRef Warren KW, Poulantzas JK, Kune GA (1966) Life after total pancreatectomy for chronic pancreatitis: clinical study of eight cases. Ann Surg 164(5):830–834PubMedPubMedCentralCrossRef
79.
go back to reference Barbier L, Jamal W, Dokmak S, Aussilhou B, Corcos O, Ruszniewski P et al (2013) Impact of total pancreatectomy: short- and long-term assessment. HPB. doi:10.1111/hpb.12054 Barbier L, Jamal W, Dokmak S, Aussilhou B, Corcos O, Ruszniewski P et al (2013) Impact of total pancreatectomy: short- and long-term assessment. HPB. doi:10.​1111/​hpb.​12054
81.
go back to reference Watanabe Y, Ohtsuka T, Matsunaga T, Kimura H, Tamura K, Ideno N et al (2015) Long-term outcomes after total pancreatectomy: special reference to survivors’ living conditions and quality of life. World J Surg 39(5):1231–1239. doi:10.1007/s00268-015-2948-1 PubMedCrossRef Watanabe Y, Ohtsuka T, Matsunaga T, Kimura H, Tamura K, Ideno N et al (2015) Long-term outcomes after total pancreatectomy: special reference to survivors’ living conditions and quality of life. World J Surg 39(5):1231–1239. doi:10.​1007/​s00268-015-2948-1 PubMedCrossRef
82.
go back to reference Parsaik AK, Murad MH, Sathananthan A, Moorthy V, Erwin PJ, Chari S et al (2010) Metabolic and target organ outcomes after total pancreatectomy: Mayo Clinic experience and meta-analysis of the literature. Clin Endocrinol 73(6):723–731. doi:10.1111/j.1365-2265.2010.03860.x CrossRef Parsaik AK, Murad MH, Sathananthan A, Moorthy V, Erwin PJ, Chari S et al (2010) Metabolic and target organ outcomes after total pancreatectomy: Mayo Clinic experience and meta-analysis of the literature. Clin Endocrinol 73(6):723–731. doi:10.​1111/​j.​1365-2265.​2010.​03860.​x CrossRef
83.
go back to reference Jaleel A, Halvatsiotis P, Williamson B, Juhasz P, Martin S, Nair KS (2005) Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. Diabetes Care 28(3):645–652PubMedCrossRef Jaleel A, Halvatsiotis P, Williamson B, Juhasz P, Martin S, Nair KS (2005) Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. Diabetes Care 28(3):645–652PubMedCrossRef
84.
go back to reference Kiviluoto T, Schroder T, Karonen SL, Kuusi T, Lempinen M, Taskinen MR (1985) Glycemic control and serum lipoproteins after total pancreatectomy. Ann Clin Res 17(3):110–115PubMed Kiviluoto T, Schroder T, Karonen SL, Kuusi T, Lempinen M, Taskinen MR (1985) Glycemic control and serum lipoproteins after total pancreatectomy. Ann Clin Res 17(3):110–115PubMed
85.
86.
go back to reference Roberts KJ, Blanco G, Webber J, Marudanayagam R, Sutcliffe RP, Muiesan P et al (2014) How severe is diabetes after total pancreatectomy? A case-matched analysis. HPB (Oxford) 16(9):814–821. doi:10.1111/hpb.12203 CrossRef Roberts KJ, Blanco G, Webber J, Marudanayagam R, Sutcliffe RP, Muiesan P et al (2014) How severe is diabetes after total pancreatectomy? A case-matched analysis. HPB (Oxford) 16(9):814–821. doi:10.​1111/​hpb.​12203 CrossRef
87.
go back to reference Epelboym I, Winner M, DiNorcia J, Lee MK, Lee JA, Schrope B et al (2014) Quality of life in patients after total pancreatectomy is comparable with quality of life in patients who undergo a partial pancreatic resection. J Surg Res 187(1):189–196. doi:10.1016/j.jss.2013.10.004 PubMedCrossRef Epelboym I, Winner M, DiNorcia J, Lee MK, Lee JA, Schrope B et al (2014) Quality of life in patients after total pancreatectomy is comparable with quality of life in patients who undergo a partial pancreatic resection. J Surg Res 187(1):189–196. doi:10.​1016/​j.​jss.​2013.​10.​004 PubMedCrossRef
88.
go back to reference Vantyghem MC1, Press M (2006) Management strategies for brittle diabetes. Ann Endocrinol (Paris) Sep;67(4):287-96 Vantyghem MC1, Press M (2006) Management strategies for brittle diabetes. Ann Endocrinol (Paris) Sep;67(4):287-96
89.
go back to reference Joanne Dintzis, Sherita Golden (2011) Post-pancreatectomy diabetes. In: Johns Hopkins Diabetes Guide 2012: Treatment and Management of Diabetes (Johns Hopkins Medicine)Christopher D. Saudek; Rita Rastogi Kalyani; Frederick L. Brancati Published by Jones & Bartlett Learning (2011) Joanne Dintzis, Sherita Golden (2011) Post-pancreatectomy diabetes. In: Johns Hopkins Diabetes Guide 2012: Treatment and Management of Diabetes (Johns Hopkins Medicine)Christopher D. Saudek; Rita Rastogi Kalyani; Frederick L. Brancati Published by Jones & Bartlett Learning (2011)
90.
go back to reference Bolli GB, Andreoli AM, Lucidi P (2011) Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 13(Suppl 1):S43–S52. doi:10.1089/dia.2011.0039 PubMed Bolli GB, Andreoli AM, Lucidi P (2011) Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 13(Suppl 1):S43–S52. doi:10.​1089/​dia.​2011.​0039 PubMed
91.
go back to reference Rickels MR, Bellin M, Toledo FG, Robertson RP, Andersen DK, Chari ST et al (2013) Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology 13(4):336–342. doi:10.1016/j.pan.2013.05.002 PubMedCrossRef Rickels MR, Bellin M, Toledo FG, Robertson RP, Andersen DK, Chari ST et al (2013) Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology 13(4):336–342. doi:10.​1016/​j.​pan.​2013.​05.​002 PubMedCrossRef
93.
go back to reference Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB et al (2009) American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 32(6):1119–1131. doi:10.2337/dc09-9029 PubMedPubMedCentralCrossRef Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB et al (2009) American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 32(6):1119–1131. doi:10.​2337/​dc09-9029 PubMedPubMedCentralCrossRef
95.
go back to reference Schmeltz LR, DeSantis AJ, Thiyagarajan V, Schmidt K, O’Shea-Mahler E, Johnson D et al (2007) Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. Diabetes Care 30(4):823–828. doi:10.2337/dc06-2184 PubMedCrossRef Schmeltz LR, DeSantis AJ, Thiyagarajan V, Schmidt K, O’Shea-Mahler E, Johnson D et al (2007) Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. Diabetes Care 30(4):823–828. doi:10.​2337/​dc06-2184 PubMedCrossRef
96.
go back to reference Walsh J, Roberts R, Bailey T (2010) Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. J Diabetes Sci Technol 4(5):1174–1181PubMedPubMedCentralCrossRef Walsh J, Roberts R, Bailey T (2010) Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. J Diabetes Sci Technol 4(5):1174–1181PubMedPubMedCentralCrossRef
97.
go back to reference Okabayashi T, Nishimori I, Yamashita K, Sugimoto T, Maeda H, Yatabe T et al (2009) Continuous postoperative blood glucose monitoring and control by artificial pancreas in patients having pancreatic resection: a prospective randomized clinical trial. Arch Surg 144(10):933–937. doi:10.1001/archsurg.2009.176 PubMedCrossRef Okabayashi T, Nishimori I, Yamashita K, Sugimoto T, Maeda H, Yatabe T et al (2009) Continuous postoperative blood glucose monitoring and control by artificial pancreas in patients having pancreatic resection: a prospective randomized clinical trial. Arch Surg 144(10):933–937. doi:10.​1001/​archsurg.​2009.​176 PubMedCrossRef
98.
go back to reference Pickup J, Keen H (2002) Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 25(3):593–598PubMedCrossRef Pickup J, Keen H (2002) Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 25(3):593–598PubMedCrossRef
99.
go back to reference Papargyri P, Ojeda Rodriguez S, Corrales Hernandez JJ, Mories Alvarez MT, Recio Cordova JM, Delgado Gomez M et al (2013) An observational 7-year study of continuous subcutaneous insulin infusion for the treatment of type 1 diabetes mellitus. Endocrinol Nutr. doi:10.1016/j.endonu.2013.09.003 Papargyri P, Ojeda Rodriguez S, Corrales Hernandez JJ, Mories Alvarez MT, Recio Cordova JM, Delgado Gomez M et al (2013) An observational 7-year study of continuous subcutaneous insulin infusion for the treatment of type 1 diabetes mellitus. Endocrinol Nutr. doi:10.​1016/​j.​endonu.​2013.​09.​003
100.
go back to reference Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R (2003) Insulin pump therapy: a meta-analysis. Diabetes Care 26(4):1079–1087PubMedCrossRef Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R (2003) Insulin pump therapy: a meta-analysis. Diabetes Care 26(4):1079–1087PubMedCrossRef
101.
go back to reference Helve E, Laatikainen L, Merenmies L, Koivisto VA (1987) Continuous insulin infusion therapy and retinopathy in patients with type I diabetes. Acta Endocrinol 115(3):313–319PubMed Helve E, Laatikainen L, Merenmies L, Koivisto VA (1987) Continuous insulin infusion therapy and retinopathy in patients with type I diabetes. Acta Endocrinol 115(3):313–319PubMed
102.
go back to reference (1995) Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 18(3):361–376 (1995) Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 18(3):361–376
104.
go back to reference Haakens K, Hanssen KF, Dahl-Jorgensen K, Vaaler S, Aagenaes O, Mosand R (1990) Continuous subcutaneous insulin infusion (CSII), multiple injections (MI) and conventional insulin therapy (CT) in self-selecting insulin-dependent diabetic patients. A comparison of metabolic control, acute complications and patient preferences. J Intern Med 228(5):457–464PubMedCrossRef Haakens K, Hanssen KF, Dahl-Jorgensen K, Vaaler S, Aagenaes O, Mosand R (1990) Continuous subcutaneous insulin infusion (CSII), multiple injections (MI) and conventional insulin therapy (CT) in self-selecting insulin-dependent diabetic patients. A comparison of metabolic control, acute complications and patient preferences. J Intern Med 228(5):457–464PubMedCrossRef
105.
go back to reference Linkeschova R, Raoul M, Bott U, Berger M, Spraul M (2002) Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 19(9):746–751PubMedCrossRef Linkeschova R, Raoul M, Bott U, Berger M, Spraul M (2002) Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 19(9):746–751PubMedCrossRef
106.
go back to reference Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P et al (2005) Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 28(3):533–538PubMedCrossRef Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P et al (2005) Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 28(3):533–538PubMedCrossRef
107.
109.
go back to reference Rickels MR, Ruedy KJ, Foster NC, Piche CA, Dulude H, Sherr JL et al (2016) Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care 39(2):264–270. doi:10.2337/dc15-1498 PubMed Rickels MR, Ruedy KJ, Foster NC, Piche CA, Dulude H, Sherr JL et al (2016) Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care 39(2):264–270. doi:10.​2337/​dc15-1498 PubMed
111.
go back to reference Tanjoh K, Tomita R, Mera K, Hayashi N (2002) Metabolic modulation by concomitant administration of insulin and glucagon in pancreatectomy patients. Hepato-Gastroenterology 49(44):538–543PubMed Tanjoh K, Tomita R, Mera K, Hayashi N (2002) Metabolic modulation by concomitant administration of insulin and glucagon in pancreatectomy patients. Hepato-Gastroenterology 49(44):538–543PubMed
115.
116.
go back to reference Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP et al (2006) International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355(13):1318–1330. doi:10.1056/NEJMoa061267 PubMedCrossRef Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP et al (2006) International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355(13):1318–1330. doi:10.​1056/​NEJMoa061267 PubMedCrossRef
119.
go back to reference Tekin Z, Garfinkel MR, Chon WJ, Schenck L, Golab K, Savari O et al (2016) Outcomes of pancreatic islet allotransplantation using the Edmonton Protocol at the University of Chicago. Transpl Direct 2(10):e105. doi:10.1097/TXD.0000000000000609 CrossRef Tekin Z, Garfinkel MR, Chon WJ, Schenck L, Golab K, Savari O et al (2016) Outcomes of pancreatic islet allotransplantation using the Edmonton Protocol at the University of Chicago. Transpl Direct 2(10):e105. doi:10.​1097/​TXD.​0000000000000609​ CrossRef
121.
go back to reference Balzano G, Maffi P, Nano R, Mercalli A, Melzi R, Aleotti F et al (2016) Autologous islet transplantation in patients requiring pancreatectomy: a broader spectrum of indications beyond chronic pancreatitis. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 16(6):1812–1826. doi:10.1111/ajt.13656 CrossRef Balzano G, Maffi P, Nano R, Mercalli A, Melzi R, Aleotti F et al (2016) Autologous islet transplantation in patients requiring pancreatectomy: a broader spectrum of indications beyond chronic pancreatitis. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 16(6):1812–1826. doi:10.​1111/​ajt.​13656 CrossRef
122.
go back to reference Ryan EA, Paty BW, Senior PA, Shapiro AM (2004) Risks and side effects of islet transplantation. Curr Diab Rep 4(4):304–309PubMedCrossRef Ryan EA, Paty BW, Senior PA, Shapiro AM (2004) Risks and side effects of islet transplantation. Curr Diab Rep 4(4):304–309PubMedCrossRef
Metadata
Title
Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia
Authors
Ajay V. Maker
Raashid Sheikh
Vinita Bhagia
Diabetes Control and Complications Trial (DCCT) Research Group
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Langenbeck's Archives of Surgery / Issue 6/2017
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-017-1603-8

Other articles of this Issue 6/2017

Langenbeck's Archives of Surgery 6/2017 Go to the issue